WO2021100631A1 - 変異糸状菌、及びそれを用いたタンパク質の製造方法 - Google Patents
変異糸状菌、及びそれを用いたタンパク質の製造方法 Download PDFInfo
- Publication number
- WO2021100631A1 WO2021100631A1 PCT/JP2020/042489 JP2020042489W WO2021100631A1 WO 2021100631 A1 WO2021100631 A1 WO 2021100631A1 JP 2020042489 W JP2020042489 W JP 2020042489W WO 2021100631 A1 WO2021100631 A1 WO 2021100631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- xyr1
- tyr
- cellulase
- Prior art date
Links
- 241000233866 Fungi Species 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 title claims description 133
- 102000004169 proteins and genes Human genes 0.000 title claims description 70
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 90
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 80
- 238000006467 substitution reaction Methods 0.000 claims abstract description 74
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 73
- 229920001184 polypeptide Polymers 0.000 claims abstract description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 71
- 230000014509 gene expression Effects 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 58
- 238000012986 modification Methods 0.000 claims abstract description 18
- 230000004048 modification Effects 0.000 claims abstract description 18
- 238000013518 transcription Methods 0.000 claims abstract description 14
- 230000035897 transcription Effects 0.000 claims abstract description 14
- 238000007792 addition Methods 0.000 claims abstract description 9
- 238000003780 insertion Methods 0.000 claims abstract description 9
- 230000037431 insertion Effects 0.000 claims abstract description 9
- 238000012217 deletion Methods 0.000 claims abstract description 7
- 230000037430 deletion Effects 0.000 claims abstract description 7
- 101100325959 Arabidopsis thaliana BHLH77 gene Proteins 0.000 claims abstract 7
- 101100378100 Mus musculus Ace3 gene Proteins 0.000 claims abstract 7
- 101100485303 Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) XYR1 gene Proteins 0.000 claims abstract 6
- 108010059892 Cellulase Proteins 0.000 claims description 96
- 229940106157 cellulase Drugs 0.000 claims description 91
- 108010002430 hemicellulase Proteins 0.000 claims description 42
- 229940059442 hemicellulase Drugs 0.000 claims description 42
- 241000223259 Trichoderma Species 0.000 claims description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 33
- 239000008103 glucose Substances 0.000 claims description 33
- 108091006106 transcriptional activators Proteins 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 abstract description 13
- 229920002678 cellulose Polymers 0.000 abstract description 13
- 229920002488 Hemicellulose Polymers 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 108
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 55
- -1 etc. Substances 0.000 description 51
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 45
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 37
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 36
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 31
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 239000002773 nucleotide Substances 0.000 description 27
- 125000003729 nucleotide group Chemical group 0.000 description 27
- 230000035772 mutation Effects 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 18
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 235000010980 cellulose Nutrition 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000411 inducer Substances 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 101150052795 cbh-1 gene Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 101150114858 cbh2 gene Proteins 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 101000955266 Homo sapiens Mediator of RNA polymerase II transcription subunit 28 Proteins 0.000 description 7
- 101000906480 Sclerotinia sclerotiorum Endoglucanase 1 Proteins 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 101100049989 Aspergillus niger xlnB gene Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 101150075580 Xyn1 gene Proteins 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 101150041186 xyn2 gene Proteins 0.000 description 5
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 4
- 101150103244 ACT1 gene Proteins 0.000 description 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 4
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 4
- 239000002551 biofuel Substances 0.000 description 4
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100272859 Arabidopsis thaliana BXL1 gene Proteins 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 108010084185 Cellulases Proteins 0.000 description 3
- 102000005575 Cellulases Human genes 0.000 description 3
- 241000123346 Chrysosporium Species 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 102000030595 Glucokinase Human genes 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000221960 Neurospora Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000223260 Trichoderma harzianum Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 108010038658 exo-1,4-beta-D-xylosidase Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 101150089778 pyr-4 gene Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910003208 (NH4)6Mo7O24·4H2O Inorganic materials 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000228138 Emericella Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 101710112457 Exoglucanase Proteins 0.000 description 1
- 101710088566 Flagellar hook-associated protein 2 Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 102100034408 Nuclear transcription factor Y subunit alpha Human genes 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 241000233654 Oomycetes Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000228178 Thermoascus Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241001494489 Thielavia Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101710188302 Xylanolytic transcriptional activator xlnR Proteins 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 101150063578 ald1 gene Proteins 0.000 description 1
- 101150023727 ald2 gene Proteins 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- LUEWUZLMQUOBSB-ZLBHSGTGSA-N alpha-maltotetraose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-ZLBHSGTGSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- OCIBBXPLUVYKCH-FYTDUCIRSA-N beta-D-cellohexaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](O[C@@H](O[C@@H]5[C@H](O[C@@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-FYTDUCIRSA-N 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- OCIBBXPLUVYKCH-UHFFFAOYSA-N cellopentanose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(OC5C(OC(O)C(O)C5O)CO)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O OCIBBXPLUVYKCH-UHFFFAOYSA-N 0.000 description 1
- FTNIPWXXIGNQQF-XHCCAYEESA-N cellopentaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FTNIPWXXIGNQQF-XHCCAYEESA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 101150066032 egl-1 gene Proteins 0.000 description 1
- 101150003727 egl2 gene Proteins 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000004127 xylose metabolism Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/885—Trichoderma
Definitions
- the present invention relates to a mutant filamentous fungus and a method for producing a protein using the mutant filamentous fungus.
- Filamentous fungi are attracting attention as degrading bacteria of plant polysaccharides because they produce various types of cellulase and hemicellulase.
- Trichoderma is attracting attention as a microorganism for producing cellulase-based biomass-degrading enzymes because it can produce cellulase and hemicellulase in large quantities at the same time.
- Inducing substances may be required for protein production such as enzymes by microorganisms.
- enzymes by microorganisms For example, in Trichoderma, the expression of major cellulase genes cbh1, cbh2, egl1 and egl2 is induced by cellulose, cellobiose, etc., and an inducer is essential for cellulase production (Non-Patent Document 2).
- microcrystalline cellulose such as Abyssel is used as an inducer for cellulase production.
- cellulose substrates are expensive and often insoluble, they impose a burden on industrial processes and are therefore difficult to use in industrial applications in terms of cost and equipment.
- Cellulase production method using soluble lactose without using cellulose as an inducer (Patent Document 3), or reaction of glucose with trichoderma-derived cellulase (including ⁇ -glucosidase, endoglucanase, cellobiohydrolase) at high temperature. So, a method for synthesizing inducible sugars such as sophorose and gentiobiose from glucose (Patent Document 4) is disclosed.
- cellulase production using inducible sugars still has disadvantages in terms of cost and process load.
- Non-Patent Document 3 It has been reported that shortening the C-terminal 140 amino acid of XYR1 causes loss of cellulase productivity of trichoderma, and that trichoderma having an A824V mutation of XYR1 causes deregulation of xylanase and increases cellulase production (non-patent). Documents 3 and 4).
- Non-Patent Document 5 reports that by combining the V821F mutation of XYR1 with the enhanced expression of ACE2 in the Trichoderma strain, the protein productivity in a medium using glucose or sucrose as a carbon source was improved.
- the gene sequence of XYR1 has an intron for 20 amino acid regions upstream of the coding region of the fungal-specific transcription factor domain (Non-Patent Document 6). Therefore, A824 and V821 of XYR1 disclosed in the above document have been once corrected to A804 and V801, respectively.
- the 20 amino acid region is translated into amino acids instead of introns. Recently, the latter finding is considered correct (eg, Non-Patent Documents 5 and 7), in which case A824 and V821 disclosed in the above document represent the correct amino acid number on the sequence of XYR1. It is regarded.
- Non-Patent Document 8 suggests that ACE3 and XYR1 interact to regulate the cellulase gene expression of Trichoderma lysei.
- Patent Document 5 discloses a method for increasing or decreasing the productivity of cellulase or the like by increasing or decreasing the expression of the tre77513 (ACE3) gene in Trichoderma lysei.
- ACE3 tre77513
- Patent Document 6 and Non-Patent Document 9 filamentous fungi that retain all 6 cysteines of the N-side Zn (II) 2 Cys type 6 DNA-binding domain and improve and express modified ACE3 lacking the C-terminal amino acid.
- II N-side Zn
- Non-Patent Document 9 also describes a filamentous fungus that improves and expresses the C-terminal deficient ACE3 and further co-expresses a wild-type of XYR1 or an A824V mutant, provided that the filamentous fungus co-expresses the XYR1. Although the effect of the drug on cellulase expression was slightly observed in the presence of the inducer, it was not observed in the absence of the inducer.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2015-39349
- Patent Document 2 Japanese Patent Application Laid-Open No. 11-512930
- Patent Document 3 Japanese Patent No. 6169077
- Patent Document 4 Japanese Patent No. 5366286 (Patent Document 5) US Pat. No. 9512415 (Patent Document 6) International Publication No.
- Non-Patent Document 1 Appl Environ Microbiol, 1997, 63: 1298-1306
- Non-Patent Document 2 Curr Genomics, 2013, 14: 230-249
- Non-Patent Document 3 BMC Genomics, 2015, 16: 326
- Biotech Biofuels, 2013, 6:62 (Non-Patent Document 5) Biotech Biofuels, 2017, 10:30 (Non-Patent Document 6) NCBI Reference Sequence: XP_006966092.1 [www.ncbi.nlm.nih.gov/protein/XP_006966092.1]
- Non-Patent Document 7 Biotech Biofuels, 2020, 13:93
- Non-Patent Document 8 J Biol Chem, 2019, doi: 10.1074 / jbc.RA119.008497
- Non-Patent Document 9 Biotech Biofuels, 2020, 13: 137
- the present invention is a method for producing a mutant filamentous fungus.
- Including modifying XYR1 and ACE3 expression in parent filamentous fungi The modification of XYR1 corresponds to positions 810 to 833 of SEQ ID NO: 1 with respect to a polypeptide consisting of SEQ ID NO: 1 or at least 90% sequence-identical amino acid sequence and functioning as a transcriptional activator of cellulase and hemicellulase. Substitution, deletion, insertion or addition of at least one amino acid residue in the region
- the modification of ACE3 expression is enhancement of expression of a polypeptide consisting of the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3 or an amino acid sequence having at least 90% sequence identical thereto. Providing a method.
- Relative protein productivity of mutant filamentous strains Protein composition analysis of mutant filamentous strain cultures: gel electrophoresis image. Relative productivity of various proteins in mutant filamentous strains. Relative productivity of various proteins in mutant filamentous strains.
- the identity of the amino acid sequence and the nucleotide sequence is calculated by the Lipman-Pearson method (Science, 1985, 227: 1435-1441). Specifically, the homology analysis (Search homology) program of the genetic information processing software Genetyx-Win (Ver.5.1.1; software development) is used, and the analysis is performed with Unit size to homology (ktup) set to 2. Is calculated by.
- amino acid sequence and a nucleotide sequence means 90% or more, preferably 92% or more, more preferably 94% or more, still more preferably 95% or more, still more preferably 96. % Or more, more preferably 98% or more, still more preferably 99% or more identity.
- the term "one or several" used with respect to the deletion, substitution, addition or insertion of amino acids and nucleotides in amino acid and nucleotide sequences is, for example, 1 to 20, preferably 1. It can mean ⁇ 16, more preferably 1-12, even more preferably 1-8, even more preferably 1-4.
- “addition" of an amino acid or nucleotide includes the addition of one or several amino acids or nucleotides to one or both ends of the sequence.
- "insertion" of an amino acid or nucleotide includes insertion of an amino acid or nucleotide into the 5'side or 3'side of a predetermined position.
- the "corresponding position" or “corresponding region” on an amino acid sequence or nucleotide sequence provides maximum homology between the target sequence and the reference sequence (eg, the amino acid sequence of SEQ ID NO: 1). It can be determined by aligning with. Alignment of amino acid sequences or nucleotide sequences can be performed using known algorithms, the procedure of which is known to those of skill in the art. For example, alignment can be performed by using the Clustal W multiple alignment program (Thompson, JD et al, 1994, Nucleic Acids Res. 22: 4673-4680) with default settings.
- Clustal W is, for example, the European Institute for Bioinformatics (European Bioinformatics Institute: EBI [www.ebi.ac.uk/index.html]) and the DNA Data Bank of Japan (DDBJ [www. It can be used on the website of ddbj.nig.ac.jp/searches-j.html]).
- EBI European Institute for Bioinformatics Institute
- DDBJ DNA Data Bank of Japan
- the position of the target sequence aligned to any position in the reference sequence by the above alignment is considered to be the "corresponding position" to that arbitrary position.
- the area sandwiched by the corresponding positions or the area consisting of the corresponding motifs is regarded as the corresponding area.
- the similarity of amino acid sequences means the ratio (%) of the number of positions where the same or similar amino acid residues are present in both sequences when two amino acid sequences are aligned to the total number of amino acid residues. ..
- a similar amino acid residue means an amino acid residue that has properties similar to each other in terms of polarity and charge among the 20 types of amino acid residues that make up a protein and causes so-called conservative substitution. To do.
- Groups of such similar amino acid residues are well known to those skilled in the art, including, for example, arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; leucine and isoleucine, respectively. , Not limited to these.
- amino acid residue refers to 20 kinds of amino acid residues constituting a protein, alanine (Ala or A), arginine (Arg or R), aspartic acid (Asn or N), aspartic acid (Asp or).
- cysteine Cys or C
- glutamine Gln or Q
- glutamic acid Glu or E
- glycine Gly or G
- histidine His or H
- isoleucine Ile or I
- leucine Leu or L
- Lysine Lys or K
- methionine Met or M
- phenylalanine Phe or F
- proline Pro or P
- serine Ser or S
- threonine Thr or T
- tryptophan Trp or W
- Tyrosine Tyr or Y
- valine Val or V
- a regulatory region such as a promoter and a "operable linkage" of a gene means that the gene and the regulatory region are linked so that the gene can be expressed under the control of the regulatory region.
- Procedures for "operable linkage" between genes and regulatory regions are well known to those of skill in the art.
- upstream and downstream with respect to a gene mean upstream and downstream in the transcription direction of the gene.
- a gene located downstream of a promoter means that the gene is present on the 3'side of the promoter in the DNA sense strand, and upstream of the gene means 5'of the gene in the DNA sense strand. Means the area on the side.
- the term "original” used for a cell function, property, or trait is used to indicate that the function, property, or trait originally exists in the cell.
- the term “foreign” is used to describe a function, property, or trait that is not originally present in the cell but is introduced from the outside.
- a “foreign" gene or polynucleotide is a gene or polynucleotide that has been externally introduced into a cell.
- the foreign gene or polynucleotide may be of the same species as the cell into which it was introduced, or of a heterologous organism (ie, a heterologous gene or polynucleotide).
- the present invention relates to a mutant filamentous fungus, a method for producing the same, and a method for producing a protein using the mutant filamentous fungus.
- the present invention relates to improving the protein productivity of filamentous fungi. Conventionally, when filamentous fungi are cultured in the presence of glucose, protein production may be suppressed by catabolite repression.
- cellulase-based biomass-degrading enzymes such as cellulase and hemicellulase in filamentous fungi
- a cellulase-inducing substance such as cellulose, sophorose, and cellooligosaccharide (cellobiose, cellotriose, cellotetraose, cellopentaose, cellohexaose, etc.)
- cellooligosaccharide cellobiose, cellotriose, cellotetraose, cellopentaose, cellohexaose, etc.
- the present inventors highly produce proteins such as cellulase and hemicellulase without using inducers conventionally essential for the production of cellulase and hemicellulase by mutant filamentous fungi modified by combining XYR1 and ACE3 expression. I found out to do.
- the filamentous fungus by making predetermined modifications to cellulase and XYR1 and ACE3, which are transcriptional activators of hemicellulase, to the filamentous fungus, the filamentous fungus is subjected to cellulase and hemi without a cellulase-inducing substance such as cellulose.
- the filamentous fungus provided by the present invention can efficiently produce a protein even in an environment in which a cellulase non-inducible carbon source such as glucose is used as a main carbon source.
- the filamentous fungus can efficiently produce proteins such as cellulase and hemicellulase without using an expensive cellulase-inducing substance. According to the present invention, it is possible to improve the efficiency and reduce the cost of protein production using filamentous fungi.
- the present invention provides a mutant filamentous fungus and a method for producing the same.
- the method for producing a mutant filamentous fungus of the present invention includes modifying XYR1 and ACE3 expression in the parent filamentous fungus.
- the order of modifying XYR1 and ACE3 expression is not limited as long as each modification is achieved.
- mycorrhizal fungi used in the present invention include, but are not limited to, filamentous fungi belonging to the phylum Omycota and the phylum Oomycota. More detailed examples include the genus Trichoderma, the genus Aspergillus, the genus Penicillium, the genus Neurospora, the genus Fusarium, the genus Chrysosporium, and the genus Chrysosporium.
- Genus Emericella, Hypocreata, Acremonium, Chrysosporium, Myceliophthora, Mycelliophthora, Pyromyces, Pyromaces
- filamentous fungi such as the genus Thermoascus and the genus Thielavia. Of these, Trichoderma filamentous fungi are preferred.
- filamentous fungi of the genus Trichoderma examples include Trichoderma reesei, Trichoderma longibraciatum, Trichoderma harzianmi, Trichoderma harzianum, and Trichoderma harzianum.
- examples include trichoderma lycee and variants thereof.
- Trichoderma Riesei QM9414 strain and its variants preferably Trichoderma Riesei PC-3-7 strain (ATCC66589), Trichoderma Riesei PCD-10 strain (FERM P-8172), Trichoderma Riesei JN13 strain, or them.
- a mutant strain of Trichoderma can be preferably used as the trichoderma.
- XYR1 (Xylanase regulator 1) is a transcriptional activator of cellulase and hemicellulase in filamentous fungi.
- XYR1 is a major factor in controlling xylanase gene expression with Zn (II) 2 Cys 6 yeast domein, and is a major factor in controlling the expression of xylanase genes, such as Trichoderma (XYR1), Fusarium (XYR1), Neurospora (XYR1), and Alpergillus (XLNR). Widely conserved in Ascomycetes except yeast.
- Trichoderma Riesei's XYR1 controls all of the xylanase / xylose metabolism genes and cellulase genes. Trichoderma Riesay's XYR1 is registered in the ncbi database (www.ncbi.nlm.nih.gov/]) as NCBI Reference Sequence: XP_0069660992.1.
- XYR1 of XP_00696609.21 consists of an amino acid sequence having a length of 920 amino acids (SEQ ID NO: 51), and is defined as a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 2. ..
- XYR1 has a 320 to 339 amino acid region encoded by the 1024 to 1083 nucleotide region of SEQ ID NO: 2, and has a total length of 940 amino acids.
- the amino acid sequence of XYR1 disclosed in the present specification is represented by SEQ ID NO: 1 having a length of 940 amino acids, and the number of the amino acid residue of XYR1 (position on the amino acid sequence). ) Is represented by the number (position) of the residue in the sequence of SEQ ID NO: 1. Further, in consideration of the above circumstances, in the present specification, the amino acid residue after position 340 in SEQ ID NO: 1 is interpreted as the amino acid residue at position [position-20 in SEQ ID NO: 1] in SEQ ID NO: 51. Should be.
- positions 810 to 833 in SEQ ID NO: 1 are positions 790 to 813 in SEQ ID NO: 51, that is, positions 810 in SEQ ID NO: 1 are positions 790 in SEQ ID NO: 51, and positions 833 in SEQ ID NO: 1 are SEQ ID NOs.
- the 813th position in 51, the 821th and 824th positions in SEQ ID NO: 1, are the 801st and 804th positions in SEQ ID NO: 51, respectively, and the same applies to other positions.
- an example of XYR1 (parent XYR1) modified in the present invention is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.
- Another example of the parent XYR1 is a polypeptide having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1 and that functions as a transcriptional activator of cellulase and hemicellulase.
- An example of an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 is an amino acid sequence in which one or several amino acid residues are deleted, substituted, added or inserted in the amino acid sequence of SEQ ID NO: 1.
- the modification of the XYR1 according to the present invention is to add a mutation of at least one amino acid residue to a region presumed to be an ⁇ -helix in the active activation domain of the parent XYR1. More specifically, the modification of XYR1 is a polypeptide consisting of the parent XYR1, the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence at least 90% identical to the amino acid sequence, and which functions as a transcriptional activator of cellulase and hemicellulase. It is carried out by mutation (ie, substitution, deletion, insertion or addition) of at least one amino acid residue in the region corresponding to positions 771 to 865 of SEQ ID NO: 1. In a preferred embodiment, the at least one amino acid residue to be mutated is located in the region corresponding to positions 810 to 833 of SEQ ID NO: 1.
- amino acid residue described above is substituted.
- the amino acid residue to be substituted is at least one selected from the group consisting of Val, Ile, Leu, Ala, Gly, Thr, and Glu, and more preferably, the following (1) and (2) :( At least one selected from the group consisting of 1) Val, Ile or Leu, (2) Ala or Gly, or at least one selected from the group consisting of Val, Ala, Thr, and Glu. Yes, more preferably at least one selected from the group consisting of Val and Ala.
- each of these amino acid residues is replaced with Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp, or Tyr.
- Preferred examples of the substitution of Val, Ile, Leu, Ala, Gly, Thr, and Glu include: Replacement of Val with Lys, Ph, Trp or Tyr; Replacement of Ile with Ph, Trp or Tyr; Replacement of Leu with Ph, Trp or Tyr; Substitution of Ala for Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr; Replacement of Gly with Val, Ile, Leu, Phe, Trp or Tyr; Replacement of Thr with Tyr; and replacement of Glu with Tyr.
- the substitution of the amino acid residue is at least one selected from the group consisting of: Substitution of Gly with Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 812 of SEQ ID NO: 1; Substitution of Val with Ph, Trp or Tyr at the position corresponding to position 814 of SEQ ID NO: 1; Substitution of Ala for Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 816 of SEQ ID NO: 1; Substitution of Thr with Tyr at the position corresponding to position 817 of SEQ ID NO: 1; Substitution of Ala for Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 820 of SEQ ID NO: 1; Substitution of Val with Lys, Ph, Trp or Tyr at the position corresponding to position 821 of SEQ ID NO: 1; Substitution of Ala for Val, Ile, Leu, Phe, Trp or Tyr at position corresponding to position 823 of SEQ
- the modification of XYR1 according to the present invention is at least one selected from the group consisting of positions corresponding to positions 817, 821, 824, 825 and 826 of SEQ ID NO: 1 with respect to parent XYR1. This is done by substituting amino acid residues at the positions. The amino acid residues substituted at the positions corresponding to the 817, 821, 824, 825 and 826 positions are as described above, respectively.
- the modification of XYR1 according to the invention is the substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 821 and 824 of SEQ ID NO: 1 with respect to parent XYR1. Is done by.
- the amino acid residue substituted at the position corresponding to the 821 position is preferably Lys, Ph, Trp or Tyr, more preferably Ph, and even more preferably Lys or Tyr.
- the amino acid residue substituted at the position corresponding to the 824 position is preferably Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr, more preferably Val, still more preferably Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr.
- the modification of XYR1 according to the invention is the amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 817, 825 and 826 of SEQ ID NO: 1 with respect to parent XYR1. It is done by substituting the group.
- the amino acid residue substituted at the position corresponding to the 817 position is preferably Tyr.
- the amino acid residue substituted at the position corresponding to the 825 position is preferably Tyr.
- the amino acid residue substituted at the position corresponding to the 826 position is preferably Val, Ile, Leu, Phe, Trp or Tyr, and more preferably Val or Trp.
- the amino acid residues at positions corresponding to positions 817, 821, 824, 825, and 826 of SEQ ID NO: 1 in the parent XYR1 are not the amino acid residues after the substitution described above, respectively.
- the amino acid residues at positions corresponding to positions 817, 821, 824, 825, and 826 of SEQ ID NO: 1 in the parent XYR1 are located at positions 817, 821, and 824 of SEQ ID NO: 1, respectively. It is the same as the amino acid residues at positions 825 and 826.
- the amino acid residue at the position corresponding to position 831 is not the amino acid residue after the substitution described above.
- the SEQ ID NOs: 1 are 812, 814, 816, 817, 820, 821, 823, 824, 825, 826, 827, 830, and 831.
- amino acid residues at the corresponding positions are at positions 812, 814, 816, 817, 820, 821, 823, 824, 825, 926, 827, and 830, respectively, of SEQ ID NO: 1.
- amino acid residue at position 831 is the same as positions 810 to 833 of SEQ ID NO: 1.
- mutagenesis techniques known in the art can be used.
- a polynucleotide encoding an amino acid sequence to be mutated (hereinafter, also referred to as a parent gene) is a polynucleotide encoding a mutated amino acid sequence (hereinafter, also referred to as a mutated gene). It is possible to express a polypeptide having the desired mutation (modified XYR1) from the mutant gene.
- a method for introducing the desired mutation into the parent gene for example, a method using homologous recombination can be mentioned.
- a parent gene in the genome of a filamentous fungus can be replaced with a mutated gene by homologous recombination.
- a specific method of homologous recombination first, a DNA construct for homologous recombination containing a mutated gene and, if necessary, a drug resistance gene or an auxotrophic gene is constructed, and this is converted into a parent filamentous fungus by a conventional method. Introduce. Next, a transformant in which the homologous recombination construct is incorporated on the genome is selected using drug resistance or auxotrophy as an index. If necessary, it may be confirmed by genome analysis or enzyme activity analysis that the obtained transformant has the desired mutation.
- a DNA construct for homologous recombination can be constructed by introducing a site-specific mutation into an isolated parent gene.
- Site-specific mutagenesis can be carried out by conventional methods in the art such as inverse PCR method, annealing method, SOE (splicing by averlap extension) -PCR (Gene, 1989, 77 (1): p61-68). it can.
- a commercially available site-directed mutagentage kit for example, Stratage II Site-Directed Mutagesis Kit, QuickChange Multi Site-Directed Mutagesis Kit, etc. can also be used.
- a vector generally used for transformation such as a plasmid can be used.
- a usual method such as a protoplast method, a protoplast PEG method, or a competent cell method can be used.
- the parent gene can be isolated by a conventional method from a filamentous strain or the like of the same species as the parent filamentous fungus. Alternatively, it may be chemically synthesized based on the nucleotide sequence of the parent gene. If necessary, the parent gene may be codon-optimized for the host (parent filamentous fungus) into which it is introduced. Information on codons used by various organisms can be obtained from Codon Usage Database ([www.kazusa.or.jp/codon/]).
- the parent gene is a poly encoding the above-mentioned parent XYR1, that is, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identical thereto and functioning as a transcriptional activator of cellulase and hemicellulase. It may be a nucleotide. Examples of such polynucleotides include the nucleotide sequence of SEQ ID NO: 2, or a polynucleotide consisting of a nucleotide sequence that is at least 90% identical in sequence.
- Site-specific mutagenesis into the parent gene can most generally be performed using a mutagenizing primer containing the nucleotide mutation to be introduced.
- the mutation primer is annealed to the region containing the sequence encoding the amino acid residue to be mutated in the parent gene, and the amino acid residue after mutation is replaced with the sequence (codon) encoding the amino acid residue to be mutated. It may be designed to include a sequence (codon) encoding. Sequences (codons) encoding amino acid residues before and after mutation can be appropriately recognized and selected by those skilled in the art based on ordinary textbooks and the like.
- site-specific mutation introduction involves ligating the upstream and downstream DNA fragments of the target region containing the nucleotide mutation to be introduced, each amplified using two sets of primers, into one by SOE-PCR. Can be done with.
- Mutation primers can be prepared by a well-known oligonucleotide synthesis method such as the phosphoramidite method (Nucleic Acids R4seaarch, 1989, 17: 7059-7071).
- the parent filamentous fungus can be subjected to mutation treatment, and then a strain having the desired mutation can be selected by genome analysis or enzyme activity analysis.
- mutation treatment include N-methyl-N'-nitro-N-nitrosoguanidine (NTG), ethylnitrosourea, and irradiation with ultraviolet rays or radiation.
- NTG N-methyl-N'-nitro-N-nitrosoguanidine
- ethylnitrosourea ethylnitrosourea
- irradiation with ultraviolet rays or radiation irradiation with ultraviolet rays or radiation.
- various alkylating agents and carcinogens can also be used as mutagens.
- ACE3 is a transcriptional activator of cellulase and hemicellulase in filamentous fungi. ACE3 is essential for transcription of the cellulase gene and some xylanase genes during lactose induction. ACE3 is also partially involved in the transcriptional regulation of xyr1.
- Tricoderma leesei's ACE3 is registered as NCBI Reference Sequence: QEM2493.1 in the ncbi database (www.ncbi.nlm.nih.gov/]), where ACE3 consists of the amino acid sequence of SEQ ID NO: 3.
- positions 523 to 734 of the amino acid sequence of SEQ ID NO: 3 are presumed to interact with XYR1, and positions 391 to 522 are presumed to be filamentous fungus-specific transcription factor domains.
- the regions 120 to 160 are presumed to be Zn (II) 2 Cys type 6 DNA binding domains.
- examples of ACE3 or a partial polypeptide thereof whose expression is enhanced in the present invention include a polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 or a partial polypeptide thereof.
- Another example of ACE3 or a partial polypeptide thereof is a polypeptide having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 3 and that functions as a transcriptional activator of cellulase and hemicellulase, or a portion thereof.
- Polypeptides can be mentioned.
- An example of an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 3 is an amino acid sequence in which one or several amino acids are deleted, substituted, added or inserted in the amino acid sequence of SEQ ID NO: 3.
- the expression of the full-length polypeptide of ACE3 may be enhanced, but the expression of a partial polypeptide thereof, preferably a polypeptide containing at least the region corresponding to positions 107 to 734 of SEQ ID NO: 3 is enhanced. do it. Therefore, examples of the ACE3 whose expression is enhanced in the present invention include a polypeptide consisting of the amino acid sequence at positions 1 to 734 of SEQ ID NO: 3 or an amino acid sequence having at least 90% of the same sequence as the amino acid sequence thereof, and a partial polypoly of ACE3. Examples of the peptide include a polypeptide consisting of the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3 or an amino acid sequence having at least 90% of the same amino acid sequence.
- the expression-enhanced ACE3 or its partial polypeptide in the present invention is the amino acid residue of the 7th to 10th amino acid residue (the amino acid residue in the region corresponding to the 725th to 728th positions of SEQ ID NO: 3) from the C-terminal of the wild-type ACE3. It holds all the basics). More preferably, the expression-enhanced ACE3 or its partial polypeptide in the present invention is the 7th to 17th amino acid residue from the C-terminal of the wild-type ACE3 (amino acid in the region corresponding to the 718 to 728 position of SEQ ID NO: 3). Residues) are all retained.
- the expression-enhanced ACE3 or a partial polypeptide thereof in the present invention retains a region corresponding to 11 amino acids (positions 724 to 734 of SEQ ID NO: 3) at the C-terminal of wild-type ACE3.
- mutation of some amino acid residues in the region corresponding to positions 724 to 734 of SEQ ID NO: 3 in the ACE3 or its partial polypeptide is allowed.
- the enhanced expression of ACE3 or a partial polypeptide thereof in the present invention means that the expression level of the ACE3 or a partial polypeptide thereof is improved.
- means for increasing the expression level of the target polypeptide include means for improving the transcription level of the gene encoding the polypeptide (hereinafter, also referred to as the target gene).
- the target gene As a means for improving the transcription amount of the target gene, for example, a control region (strong control region) that strongly promotes transcription of the gene is substituted or inserted into the control region of the target gene on the genome of the filamentous fungus.
- the strong control region may be operably linked to the target gene.
- the gene fragment of the target gene which is operably linked to the control region (preferably the strong control region) as needed, is introduced into the genome or plasmid of the filamentous fungus to express the target gene in the cell.
- the control region preferably the strong control region
- control region that can be used to improve the transcription amount, for a gene whose transcription amount does not decrease even under high glucose conditions, for example, for trichoderma filamentous fungi, glyceraldehyde-3-phosphate dehydrogenase (gpd), pyruvate dehydrogenase (pdc), enolese (eno), alcohol dehydrogenase (adh), triose phosphate generase (tpi), aldolase (fba), pyruvate kinase (pyruvate kinase ⁇ ) Dehydrogenase I (ald1), alcohol dehydrogenase II (ald2), pyruvate dehydrogenase (pda), glucokinase (glk), glucokinase (glk), actin (act1), transfection gene (act1), transfection gene, etc.
- preferable high control regions include control regions such as
- the target gene can be isolated by a conventional method from a filamentous strain or the like of the same species as the parent filamentous fungus. Alternatively, it may be chemically synthesized based on the nucleotide sequence of the gene of the parent filamentous fungus.
- Preferred examples of the target gene are a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 4, a polynucleotide consisting of a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 4 and functioning as a transcriptional activator of cellulase and hemicellulase.
- the polynucleotides encoding the same, or their partial polynucleotides, may be mentioned.
- nucleotide sequence that is at least 90% identical to SEQ ID NO: 4 is a nucleotide sequence in which one or several nucleotides are deleted, substituted, added or inserted in the sequence of SEQ ID NO: 4.
- Preferred examples of the partial polynucleotide include the polynucleotide encoding the partial polypeptide of ACE3 described above.
- the expression level of ACE3 or a partial polypeptide thereof in the mutant strain of the present invention is improved as compared with the parent filamentous fungus.
- the transcription amount of the gene encoding ACE3 or a partial polypeptide thereof in the mutant strain of the present invention is improved as compared with the parent filamentous fungus.
- the expression level of a gene or polypeptide can be quantified by known means such as quantitative PCR, microarray, Western blotting, ELISA, HPLC and the like.
- the mutant filamentous fungus of the present invention produced by the above procedure contains the modified XYR1 obtained by the above-mentioned modification of XYR1, and as described above, the expression of ACE3 or a partial polypeptide thereof is higher than that of the parent filamentous fungus. It has been strengthened.
- the mutant filamentous fungus of the present invention is a partial polypeptide of ACE3 operably linked to a control region (preferably a strongly control region) (preferably the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3 or at least the amino acid sequence thereof.
- a control region preferably a strongly control region
- a gene encoding (a polypeptide consisting of a 90% sequence identical amino acid sequence) has been introduced, thereby enhancing the expression of the partial polypeptide of the ACE3.
- the modified XYR1 contained in the mutant filamentous fungus of the present invention is a region corresponding to positions 771 to 865 of SEQ ID NO: 1 with respect to SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity identical thereto, preferably.
- a polypeptide consisting of an amino acid sequence in which at least one amino acid residue in the region corresponding to positions 810 to 833 is substituted, deleted, inserted or added, and which functions as a transcriptional activator of cellulase and hemicellulase.
- the modified XYR1 contained in the mutant filamentous fungus of the present invention is located in a region corresponding to positions 771 to 865 of SEQ ID NO: 1 with respect to SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identical thereto.
- the modified XYR1 has at least 90% sequence identity with SEQ ID NO: 1 and has the following (a)-(m): (A) Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 812 of SEQ ID NO: 1. (B) Ph, Trp or Tyr at the position corresponding to position 814 of SEQ ID NO: 1; (C) Val, Ile, Leu, Phe, Trp or Tyr; at the position corresponding to position 816 of SEQ ID NO: 1. (D) Tyr at the position corresponding to position 817 of SEQ ID NO: 1; (E) Val, Ile, Leu, Phe, Trp or Tyr; at the position corresponding to position 820 of SEQ ID NO: 1.
- the modified XYR1 has one or more of the (a), (c), (e), (g), (h), and (j) and / or the (b). , (F), (k), (l), (m). More preferably, the modified XYR1 has one or more of the (c), (e), (g), (h), (j) and / or the (b), (f). Have any one or more of.
- the modified XYR1 is at least 90% sequence identical to SEQ ID NO: 1 and is any one of (d), (f), (h), (i) and (j). It is a polypeptide consisting of an amino acid sequence having the above and functions as a transcriptional activator of cellulase and hemicellulase.
- the modified XYR1 is at least 90% sequence identical to SEQ ID NO: 1 and: Lys, Ph, Trp or Tyr, preferably Ph, more preferably Lys or Tyr; at the position corresponding to position 821 of SEQ ID NO: 1. Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr, preferably Val, more preferably Glu, Ile, Leu, Lys, Ph, Thr, Trp or at the position corresponding to position 824 of SEQ ID NO: 1.
- Tyr A polypeptide consisting of an amino acid sequence having at least one amino acid residue selected from the group consisting of and functioning as a transcriptional activator of cellulase and hemicellulase.
- the modified XYR1 is at least 90% sequence identical to SEQ ID NO: 1 and: Tyr at the position corresponding to position 817 of SEQ ID NO: 1; Tyr; and at the position corresponding to position 825 of SEQ ID NO: 1.
- a polypeptide consisting of an amino acid sequence having at least one amino acid residue selected from the group consisting of and functioning as a transcriptional activator of cellulase and hemicellulase.
- the mutant filamentous fungus of the present invention can express cellulase-based biomass-degrading enzymes such as cellulase and hemicellulase even in the absence of cellulase-inducing substances such as cellulose, sophorose and cellooligosaccharide. Furthermore, the mutant filamentous fungus can efficiently produce a protein even in an environment in which a cellulase-inducible carbon source such as glucose is used as a main carbon source, for example, even in the absence of a cellulase-inducible substance.
- a cellulase-inducible carbon source such as glucose
- the present invention provides a method for producing a protein using the mutant filamentous fungus of the present invention described above.
- the mutant filamentous fungus of the present invention is cultured. By culturing, the protein of interest is produced and accumulated in the culture. By separating the target protein from the culture, the target protein can be produced.
- the target protein to be produced examples include cellulase-based biomass-degrading enzymes such as cellulase and hemicellulase, exoglucanase, endoglucanase, ⁇ -glucosidase, protease, lipase, mannase, arabinase, galactase, and amylase.
- the target protein may be one type of protein or a mixture of a plurality of types of proteins.
- the target protein is a cellulase-based biomass-degrading enzyme, more preferably cellulase and / or hemicellulase, and even more preferably cellulase and hemicellulase.
- the hemicellulase include xylanase, ⁇ -xylosidase, ⁇ -arabinofuranosidase and the like, of which xylanase is preferable.
- the target protein may be a heterologous protein that is not originally produced by filamentous fungi.
- a recombinant filamentous fungus is prepared by inserting a gene encoding a heterologous protein into the mutant filamentous fungus of the present invention, and the recombinant filamentous fungus is cultured to obtain a protein containing the heterologous protein. be able to.
- the heterologous protein can be secreted and produced in a culture.
- the medium used for protein production may be either a synthetic medium or a natural medium as long as it contains components necessary for normal growth of filamentous fungi and protein production such as carbon source, nitrogen source, inorganic salt and vitamin.
- the carbon source may be any carbon source that can be assimilated by the mutant filamentous fungus, for example, sugars such as glucose and fructose, sugar alcohols such as sorbitol, alcohols such as ethanol and glycerol, and acetic acid. Organic acids and the like can be mentioned. These can be used alone or in combination of two or more.
- the mutant filamentous fungus is cultured in an environment in which a cellulase non-inducible carbon source is used as a main carbon source.
- a cellulase non-inducible carbon source examples include glucose, fructose, sucrose, maltose, glycerol and the like. Of these, glucose is preferable in terms of cost.
- the target protein to be produced is a cellulase-based biomass-degrading enzyme
- the culture by this method may be carried out in the presence of a cellulase-inducing substance such as cellulose, sophorose and cellooligosaccharide, but the inducible substance is absent.
- the mutant filamentous fungi are cultured while feeding a non-inducible carbon source such as glucose. May be good. At this time, culturing by dissolving the cellulase non-inducible carbon source, for example, glucose in aqueous ammonia containing a nitrogen source or an aqueous solution containing an ammonium salt, and pouring the solution into culturing is performed. It is preferable because it can suppress foaming inside.
- nitrogen source examples include ammonia, ammonium salts such as ammonium sulfate, nitrogen compounds such as amines, peptone, and natural nitrogen sources such as soybean hydrolyzate.
- Examples of the inorganic salt include potassium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, potassium carbonate and the like.
- vitamins examples include biotin and thiamine. Further, if necessary, a substance required for growth by the filamentous fungus of the present invention can be added.
- Culturing is preferably carried out under aerobic conditions such as shaking culture and aeration stirring culture.
- the culture temperature is preferably 10 ° C. or higher, more preferably 20 ° C. or higher, more preferably 25 ° C. or higher, and preferably 50 ° C. or lower, more preferably 42 ° C. or lower, more preferably 35 ° C. or lower. Further, it is preferably 10 to 50 ° C, more preferably 20 to 42 ° C, and more preferably 25 to 35 ° C.
- the pH at the time of culturing is 3 to 9, preferably 4 to 5.
- the culture time is 10 hours to 10 days, preferably 2 to 7 days.
- the target protein is separated from the obtained culture by a conventional method. For example, by collecting the culture, performing cell crushing treatment by ultrasonic waves, pressurization, etc. as necessary, and appropriately combining filtration, centrifugation, ultrafiltration, salting out, dialysis, chromatography, etc., the said.
- the target protein can be separated from the culture.
- the degree of separation of the target protein is not particularly limited.
- the culture supernatant and its crudely separated purified product can be obtained as a composition containing the target protein.
- the present invention also includes the following substances, manufacturing methods, uses, methods, etc. as exemplary embodiments. However, the present invention is not limited to these embodiments.
- a method for producing a mutant filamentous fungus Including modifying XYR1 and ACE3 expression in parent filamentous fungi
- the modification of XYR1 corresponds to positions 810 to 833 of SEQ ID NO: 1 with respect to a polypeptide consisting of SEQ ID NO: 1 or at least 90% sequence-identical amino acid sequence and functioning as a transcriptional activator of cellulase and hemicellulase.
- the modification of ACE3 expression comprises enhancing the expression of a polypeptide consisting of the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3 or an amino acid sequence that is at least 90% identical to the amino acid sequence and functions as a transcriptional activator of cellulase and hemicellulase.
- the at least one amino acid residue is It is preferably at least one selected from the group consisting of Val, Ile, Leu, Ala, Gly, Thr, and Glu.
- Substitution of at least one amino acid residue Preferably: Substitution of Thr with Tyr at the position corresponding to position 817 of SEQ ID NO: 1; Substitution of Val with Lys, Ph, Trp or Tyr at the position corresponding to position 821 of SEQ ID NO: 1; Substitution of Ala for Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr at the position corresponding to position 824 of SEQ ID NO: 1; Substitution of Glu with Tyr at the position corresponding to position 825 of SEQ ID NO: 1; Substitution of Ala for Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 826 of SEQ ID NO: 1.
- At least one selected from the group consisting of [5] The method described.
- the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3, or an amino acid sequence that is at least 90% identical to this Preferably, it retains all the amino acid residues in the region corresponding to positions 725 to 728 of SEQ ID NO: 3, and more preferably, it retains all the amino acid residues in the region corresponding to positions 718 to 728 of SEQ ID NO: 3. And Or Preferably, it retains a region corresponding to positions 724 to 734 of SEQ ID NO: 3, but some amino acid residues in the region may be mutated.
- the method according to any one of [1] to [6].
- the transcription amount of the gene encoding the polypeptide is improved by introducing the gene encoding the polypeptide operably linked to the control region into the filamentous fungus.
- the method described. [10]
- the XYR1 is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 51 registered as XP_0069666692, or is composed of an amino acid sequence having at least 90% sequence identical to the amino acid sequence of SEQ ID NO: 51, and cellulase and hemi.
- Substitution of at least one amino acid residue is preferably described below: Substitution of Thr with Tyr at the position corresponding to position 797 of SEQ ID NO: 51; Substitution of Val with Lys, Ph, Trp or Tyr at the position corresponding to position 801 of SEQ ID NO: 51; Substitution of Ala for Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr at the position corresponding to position 804 of SEQ ID NO: 51; Substitution of Glu with Tyr at the position corresponding to position 805 of SEQ ID NO: 51; Substitution of Ala for Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 806 of SEQ ID NO: 51, At least one selected from the group consisting of The method according to any one of [1] to [9].
- the mutant filamentous fungus Preferably, the catabolite repression is alleviated as compared to the parent filamentous fungus. More preferably, the cellulase is expressed in the absence of a cellulase-inducing substance.
- the filamentous fungus is preferably a Trichoderma spp.
- the Trichoderma spp. Is preferably Trichoderma Risei or a mutant strain thereof.
- [14] A method for producing a protein, which comprises culturing a filamentous fungus produced by the method according to any one of the above [1] to [13].
- the protein is preferably cellulase and / or hemicellulase.
- the culture is preferably carried out in the presence of glucose.
- modified XYR1 at least one amino acid residue in the region corresponding to positions 810 to 833 of SEQ ID NO: 1 is substituted, deleted, inserted or inserted into the amino acid sequence of SEQ ID NO: 1 or at least 90% sequence identical thereto.
- the partial polypeptide of ACE3 is a polypeptide consisting of the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3 or an amino acid sequence having at least 90% sequence identical thereto, and functions as a transcriptional activator of cellulase and hemicellulase. , Mutant filamentous fungus.
- the amino acid sequence at positions 107 to 734 of SEQ ID NO: 3 or an amino acid sequence that is at least 90% identical to the amino acid sequence is Preferably, it retains all the amino acid residues in the region corresponding to positions 725 to 728 of SEQ ID NO: 3, and more preferably, it retains all the amino acid residues in the region corresponding to positions 718 to 728 of SEQ ID NO: 3.
- the mutant filamentous fungus according to [17] which retains a region corresponding to positions 724 to 734 of SEQ ID NO: 3, although some amino acid residues in the region may be mutated.
- the modified XYR1 is selected from the group consisting of the following in the region corresponding to positions 810 to 833 of SEQ ID NO: 1 with respect to the amino acid sequence of SEQ ID NO: 1 or at least 90% sequence identical thereto.
- Substitution of at least one amino acid residue Replacement of Val with Lys, Ph, Trp or Tyr; Replacement of Ile with Ph, Trp or Tyr; Replacement of Leu with Ph, Trp or Tyr; Substitution of Ala for Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr; and Replacement of Gly with Val, Ile, Leu, Phe, Trp or Tyr; Substitution of Thr to Tyr; and Substitution of Glu to Tyr, A polypeptide consisting of the amino acid sequence of the cellulase and functioning as a transcriptional activator of cellulase and hemicellulase.
- the mutant filamentous fungus according to [17] or [18].
- the modified XYR1 has at least 90% sequence identical to SEQ ID NO: 1 and has the following (a) to (m): (A) Val, Ile, Leu, Phe, Trp or Tyr at the position corresponding to position 812 of SEQ ID NO: 1. (B) Ph, Trp or Tyr at the position corresponding to position 814 of SEQ ID NO: 1; (C) Val, Ile, Leu, Phe, Trp or Tyr; at the position corresponding to position 816 of SEQ ID NO: 1. (D) Tyr at the position corresponding to position 817 of SEQ ID NO: 1; (E) Val, Ile, Leu, Phe, Trp or Tyr; at the position corresponding to position 820 of SEQ ID NO: 1.
- the modified XYR1 is at least 90% sequence identical to SEQ ID NO: 1 and: Lys, Ph, Trp or Tyr, preferably Ph, more preferably Lys or Tyr; at the position corresponding to position 821 of SEQ ID NO: 1. Val, Glu, Ile, Leu, Lys, Ph, Thr, Trp or Tyr, preferably Val, more preferably Glu, Ile, Leu, Lys, Ph, Thr, Trp or at the position corresponding to position 824 of SEQ ID NO: 1.
- Tyr A polypeptide consisting of an amino acid sequence having at least one amino acid residue selected from the group consisting of and functioning as a transcriptional activator of cellulase and hemicellulase.
- the modified XYR1 is at least 90% sequence identical to SEQ ID NO: 1 and: Tyr at the position corresponding to position 817 of SEQ ID NO: 1; Tyr; and at the position corresponding to position 825 of SEQ ID NO: 1. Val, Ile, Leu, Phe, Trp or Tyr, preferably Val or Trp, at the position corresponding to position 826 of SEQ ID NO: 1.
- a polypeptide consisting of an amino acid sequence having at least one amino acid residue selected from the group consisting of and functioning as a transcriptional activator of cellulase and hemicellulase.
- Example 1 Construction of plasmid DNA for gene transfer The following DNA fragments 1 to 5 were prepared by PCR using the genomic DNA of Trichoderma Riesei as a template.
- Fragment 1 Promoter region about 1.5 kbp upstream of act1 gene (TRIREDRAFT_44504)
- Fragment 2 xyr1 gene (SEQ ID NO: 2, about 3.0 kbp)
- Fragment 3 Partial polypeptide of ACE3 (107-734 of SEQ ID NO: 3) Nucleotide encoding (position) (881 to 2918 nucleotide region of SEQ ID NO: 4, about 2.0 kbp)
- fragment 4 terminator region of about 0.6 kbp downstream of cbh1 gene (TRIREDRAFT_44504)
- fragment 5 pyr4 gene (TRIREDRAFT_74020) ) About 2.7 kbp region.
- Fragments 1 and 2 were combined to construct cassette 1: Pact1-XYR1. Fragments 1 and 3 were combined to construct cassette 2: Patch1-ACE3. A transformation marker fragment was prepared in which a fragment 6 of about 0.5 kbp and a fragment 7 of about 1.0 kbp were arranged as homologous sequences for pop-out upstream and downstream of the fragment 5, respectively. Fragment 4 and the transformation marker fragment were combined to construct cassette 3: Tcbh1-pyr4. Binding of DNA fragments was performed according to the In-Fusion HD Cloning Kit (Takara Bio) protocol. Table 1 shows the constructed cassette, the DNA fragments contained therein, and the primers used to construct the cassette.
- Table 1 shows the constructed cassette, the DNA fragments contained therein, and the primers used to construct the cassette.
- Cassettes 1 and 3 were bound and inserted into the HincII restriction enzyme cut point of pUC118 (Takara Bio) to construct the xyr1 constitutive expression plasmid pUC-Pact1-XYR1.
- cassettes 2 and 3 were bound and inserted into the HincII restriction enzyme cut point of pUC118 (Takara Bio) to construct the ace3 constitutive expression plasmid pUC-Pact1-ACE3.
- PUC-Pact1-XYR1 V821F
- pUC-Pact1-XYR1 A824V
- pUC-Pact1-XYR1 V821F
- pUC-Pact1-XYR1 A824V
- pUC-Pact1-XYR1 V821F
- V821F is a plasmid encoding a mutant XYR1 (V821F) in which the amino acid sequence of SEQ ID NO: 2 is substituted with the amino acid of V821F.
- pUC-Pact1-XYR1 (A824V) is a plasmid encoding a mutant XYR1 (A824V) in which the amino acid sequence of SEQ ID NO: 2 is substituted with A824V.
- the constructed plasmids pUC-Pact1-ACE3, pUC-Pact1-XYR1 (V821F), and pUC-Pact1-XYR1 (A824V) were replicated.
- the plasmid was introduced into competent cells Escherichia coli DH5 ⁇ Compentent Cells (Takarabio), cultured in LB medium supplemented with ampicillin (37 ° C., 1 day), and from the cultured cells using NucleoSpin TM plasmid (Machray Nagel). The plasmid was recovered and purified.
- Example 2 Preparation of mutant strain of filamentous fungus
- the Trichoderma Riesei JN13 ⁇ pyr4 strain was transformed by introducing the plasmid constructed in Example 1.
- the plasmid was introduced by the protoplast PEG method (Biotechnol Bioeng, 2012, 109 (1): 92-99).
- Transformants as a marker of pyr4 gene the selective medium (2% glucose, 1.1 M sorbitol, 2% agar, 0.2% KH 2 PO 4 ( pH5.5), 0.06% CaCl 2 ⁇ 2H 2 at any% w / v%); O , 0.06% CsCl 2, 0.06% MgSO 4 ⁇ 7H 2 O, 0.5% (NH 4) 2 SO 4, 0.1% Trace element1 Selected.
- Trace element1 is as follows: 0.5g FeSO 4 ⁇ 7H 2 O , 0.2g CoCl 2, 0.16g MnSO 4 ⁇ H 2 O, in distilled water 0.14g ZnSO 4 ⁇ 7H 2 O Mess up to 100 mL. From the obtained transformants, it was confirmed by PCR that the gene fragment of interest was inserted, and the JN13_ACE3 strain into which pUC-Pact1-ACE3 was introduced and the pUC-Pact1-XYR1 (V821F) were introduced. The JN13_XYR1 (V821F) strain was obtained.
- the JN13_ACE3 strain highly expresses ACE3 with the ace3 constitutive expression plasmid pUC-Pact1-ACE3.
- the JN13_XYR1 (V821F) strain expresses the mutant XYR1 (V821F).
- Example 3 Culturing of a filamentous fungus mutant strain
- the filamentous fungus strain obtained in Example 2 was cultured to produce a protein.
- 50 mL of the medium was placed in a 500 mL flask, the spores of the strain prepared in Example 2 were inoculated to 1 ⁇ 10 5 cells / mL, and cultured with shaking at 28 ° C. and 220 rpm (Pris). Made by PRXYg-98R).
- the medium composition is as follows.
- Trace element 2 1% glucose, 0.14% (NH 4) 2 SO 4, 0.2% KH 2 PO 4, 0.03% CaCl 2 ⁇ 2H 2 O, 0.03% MgSO 4 ⁇ 7H 2 O, 0.1 % High Polypeptone N, 0.05% Bacto Yeast extract, 0.1% Tween 80, 0.1% Trace element2, 50 mM tartrate buffer (pH 4.0) (% are all w / v%).
- the composition of Trace element 2 is as follows.
- the medium composition is as follows.
- Example 4 Protein Concentration Measurement The protein concentration of the culture of Example 3 was measured by the bradford method. In the bradford method, the Quick Start protein assay (BioRad) was used, and the amount of protein was calculated based on the calibration curve prepared using bovine gamma globulin as a standard protein.
- FIG. 1 shows the relative protein productivity of each strain when the protein productivity of the JN13 strain (parent strain) in the culture using only glucose as a carbon source (glucose culture) is 1. Compared with the culture in the presence of cellulose, the protein productivity of the parent strain JN13 in the glucose culture was significantly reduced.
- Example 5 Protein Composition Analysis The protein composition of the culture of Example 3 was analyzed. For the analysis, Mini PROTENA TGX Stain-Free Gels (Any KD, 15well, BIORAD) was used. As a standard, Precision Plus Protein Unsteined standard was used. The appropriately diluted culture of Example 3 and Buffer were mixed and treated at 99 ° C. for 5 minutes, applied to a gel, and electrophoresed at 200 V for 35 minutes. From the obtained image file (FIG. 2), the band intensity ratio was calculated using analysis software (Image Lab), and the composition ratio of the produced protein was calculated. The amount of each protein produced was determined from the composition ratio and the protein concentration determined in Example 4. Next, the relative productivity of each protein in each strain was calculated, with the protein productivity of only the XYR1 mutation (XYR1 (V821F) strain) as 1.
- XYR1 mutation XYR1 (V821F) strain
- the composition ratio of the product is closer to that of the parent strain in the presence of cellulose, and the composition ratio of the product is closer to that of the parent strain in the presence of cellulose, and CBH1 is a major cellulase, as compared with the XYR1 single mutant strain and the ACE3 high expression strain. , CBH2 and EG1 productivity were significantly improved.
- Example 6 Preparation of filamentous fungus mutant strain The amino acid substitution of T817Y was carried out by PCR using the primers of SEQ ID NOs: 23 and 24 shown in Table 4 using pUC-Pact1-XYR1 as a template in the same procedure as in Example 1. A plasmid pUC-Pact1-XYR1 (T817Y) expressing the mutant XYR1 was constructed.
- the primers shown in Table 4 are used to express mutant XYR1 with amino acid substitutions of V821Y, V821K, A824I, A824L, A824F, A824W, A824Y, A824T, A824K, A824E, E825Y, A826V, and A826W.
- Each plasmid was constructed.
- the constructed plasmid was transformed into the JN13_ACE3 ⁇ pyr4 strain by the same method as in Example 2 to obtain a filamentous fungus mutant strain into which ACE3 and the above-mentioned mutant XYR1 were introduced.
- JN13_XYR1 (V821F) + ACE3 strain, JN13_XYR1 (A824V) + ACE3 strain, XYR1 single mutant strain (JN13_XYR1 (V821F)), and ACE3 high expression strain (JN13_ACE3) prepared in Example 2 were used.
- Glucose culture was carried out according to the method described in Example 3, and then protein concentration measurement and protein composition analysis of the culture were carried out according to the method described in Examples 4 and 5.
- BXL1 is ⁇ -xylosidase BXL1
- CBH1 is cellulase CBH1
- CBH2 + EG1 is cellulase CBH2 and EG1
- XYN1 + XYN2 is xylanase XYN1 and XYN2, and other proteins.
- a filamentous strain that highly expresses ACE3 and expresses mutant XYR1 (T817Y, V821Y, V821K, A824I, A824L, A824F, A824W, A824Y, A824T, A824K, A824E, E825Y, A826V and A826W) prepared in this example. All produced proteins with the same compositions as the JN13_XYR1 (V821F) + ACE3 strain and the JN13_XYR1 (A824V) + ACE3 strain prepared in Example 2.
- the productivity of not only xylanase but also the major cellulases CBH1, CBH2 and EG1 was significantly improved as compared with the XYR1 single mutation.
- the effective mutation of XYR1 is not limited to V821F and A824V, but glucose that adds at least one amino acid mutation to the region presumed to be ⁇ -helix in the active activation domain of XYR1 (usually glucose that causes catabolite repression).
- the mutant XYR1 exhibiting the property of improving protein productivity even when the drug was used was effective for the production of cellulase and xylanase in the absence of an inducer.
- the cellulase / xylanase gene can be obtained in the same manner as when a cellulase-inducible substance such as cellulose is used. It was shown that the promoter can be activated and protein production can be efficiently induced.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(特許文献2)特表平11-512930号公報
(特許文献3)特許第6169077号公報
(特許文献4)特許第5366286号公報
(特許文献5)米国特許第9512415号公報
(特許文献6)国際公開公報第2018/067599号
(非特許文献1)Appl Environ Microbiol, 1997, 63:1298-1306
(非特許文献2)Curr Genomics, 2013, 14:230-249
(非特許文献3)BMC Genomics, 2015, 16:326
(非特許文献4)Biotech Biofuels, 2013, 6:62
(非特許文献5)Biotech Biofuels, 2017, 10:30
(非特許文献6)NCBI Reference Sequence: XP_006966092.1 [www.ncbi.nlm.nih.gov/protein/XP_006966092.1]
(非特許文献7)Biotech Biofuels, 2020, 13:93
(非特許文献8)J Biol Chem, 2019, doi:10.1074/jbc.RA119.008497
(非特許文献9)Biotech Biofuels, 2020, 13:137
親糸状菌におけるXYR1及びACE3発現を改変することを含み、
該XYR1の改変が、配列番号1又はこれと少なくとも90%配列同一なアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドに対する、配列番号1の810~833位に相当する領域における少なくとも1つのアミノ酸残基の置換、欠失、挿入又は付加であり、
該ACE3発現の改変が、配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列からなるポリペプチドの発現強化である、
方法、を提供する。
上記の事情を考慮して、特に説明しない場合、本明細書で開示されるXYR1のアミノ酸配列は、940アミノ酸長の配列番号1で表され、XYR1のアミノ酸残基の番号(アミノ酸配列上の位置)は、配列番号1の配列における残基の番号(位置)で表される。また上記の事情を考慮して、本明細書においては、配列番号1における340位以降のアミノ酸残基は、配列番号51における[配列番号1における位置-20]位のアミノ酸残基と解釈されるべきである。例えば、配列番号1における810~833位は、配列番号51における790~813位であり、つまり、配列番号1における810位は配列番号51における790位であり、配列番号1における833位は配列番号51における813位であり、配列番号1における821位及び824位は、それぞれ配列番号51における801位及び804位であり、その他の位置についても同様である。
ValのLys、Phe、Trp又はTyrへの置換;
IleのPhe、Trp又はTyrへの置換;
LeuのPhe、Trp又はTyrへの置換;
AlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
GlyのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
ThrのTyrへの置換;及び
GluのTyrへの置換。
配列番号1の812位に相当する位置におけるGlyのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の814位に相当する位置におけるValのPhe、Trp又はTyrへの置換;
配列番号1の816位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の817位に相当する位置におけるThrのTyrへの置換;
配列番号1の820位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の821位に相当する位置におけるValのLys、Phe、Trp又はTyrへの置換;
配列番号1の823位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の824位に相当する位置におけるAlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
配列番号1の825位に相当する位置におけるGluのTyrへの置換;
配列番号1の826位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の827位に相当する位置におけるIleのPhe、Trp又はTyrへの置換;
配列番号1の830位に相当する位置におけるIleのPhe、Trp又はTyrへの置換;及び、
配列番号1の831位に相当する位置におけるLeuのPhe、Trp又はTyrへの置換。
別の一例において、親XYR1における配列番号1の810~833位に相当する領域のアミノ酸配列は、配列番号1の810~833位と同じである。
ValのLys、Phe、Trp又はTyrへの置換;
IleのPhe、Trp又はTyrへの置換;
LeuのPhe、Trp又はTyrへの置換;
AlaのGlu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
GlyのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
ThrのTyrへの置換;及び
GluのTyrへの置換、
がなされたアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである。
(a)配列番号1の812位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(b)配列番号1の814位に相当する位置におけるPhe、Trp又はTyr;
(c)配列番号1の816位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(d)配列番号1の817位に相当する位置におけるTyr;
(e)配列番号1の820位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(f)配列番号1の821位に相当する位置におけるLys、Phe、Trp又はTyr;
(g)配列番号1の823位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(h)配列番号1の824位に相当する位置におけるVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyr;
(i)配列番号1の825位に相当する位置におけるGluのTyrへの置換;
(j)配列番号1の826位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(k)配列番号1の827位に相当する位置におけるPhe、Trp又はTyr;
(l)配列番号1の830位に相当する位置におけるPhe、Trp又はTyr;及び、
(m)配列番号1の831位に相当する位置におけるPhe、Trp又はTyr、
からなる群より選択される少なくとも1つのアミノ酸残基を有するアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである。
さらに好ましくは、該改変XYR1は、該(a)、(c)、(e)、(g)、(h)、(j)のいずれか1つ以上を有するか、及び/又は該(b)、(f)、(k)、(l)、(m)のいずれか1つ以上を有する。さらに好ましくは、該改変XYR1は、該(c)、(e)、(g)、(h)、(j)のいずれか1つ以上を有するか、及び/又は該(b)、(f)のいずれか1つ以上を有する。
配列番号1の821位に相当する位置におけるLys、Phe、Trp又はTyr、好ましくはPhe、より好ましくはLys又はTyr;及び、
配列番号1の824位に相当する位置におけるVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyr、好ましくはVal、より好ましくはGlu、Ile、Leu、Lys、Phe、Thr、Trp又はTyr、
からなる群より選択される少なくとも1つのアミノ酸残基を有するアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである。
配列番号1の817位に相当する位置におけるTyr;
配列番号1の825位に相当する位置におけるTyr;及び、
配列番号1の826位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr、好ましくはVal又はTrp、
からなる群より選択される少なくとも1つのアミノ酸残基を有するアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである。
親糸状菌におけるXYR1及びACE3発現を改変することを含み、
該XYR1の改変が、配列番号1又はこれと少なくとも90%配列同一なアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドに対する、配列番号1の810~833位に相当する領域における少なくとも1つのアミノ酸残基の置換、欠失、挿入又は付加であり、
該ACE3発現の改変が、配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドの発現強化である、
方法。
〔2〕前記少なくとも1つのアミノ酸残基が、
好ましくはVal、Ile、Leu、Ala、Gly、Thr、及びGluからなる群より選択される少なくとも1つであり、
より好ましくは下記(1)及び(2):(1)Val、Ile又はLeu、(2)Ala又はGly、からなる群より選択される少なくとも1つであるか、あるいは、Val、Ala、Thr、及びGluからなる群より選択される少なくとも1つであり、
さらに好ましくはVal及びAlaからなる群より選択される少なくとも1つであり、
かつ、好ましくは、該少なくとも1つのアミノ酸残基が置換される、
〔1〕記載の方法。
〔3〕好ましくは、前記少なくとも1つのアミノ酸残基が、配列番号1の817位、821位、824位、825位及び826位に相当する位置におけるアミノ酸残基からなる群より選択される少なくとも1つである、〔2〕記載の方法。
〔4〕好ましくは、前記少なくとも1つのアミノ酸残基がそれぞれ、Val、Glu、Ile、Leu、Lys、Phe、Thr、Trp、又はTyrに置換される、〔2〕又は〔3〕記載の方法。
〔5〕前記少なくとも1つのアミノ酸残基の置換が、
好ましくは、以下:
ValのLys、Phe、Trp又はTyrへの置換;
IleのPhe、Trp又はTyrへの置換;
LeuのPhe、Trp又はTyrへの置換;
AlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
GlyのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
ThrのTyrへの置換;及び
GluのTyrへの置換、
からなる群より選択される少なくとも1つであり、
より好ましくは、以下:
配列番号1の812位に相当する位置におけるGlyのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の814位に相当する位置におけるValのPhe、Trp又はTyrへの置換;
配列番号1の816位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の817位に相当する位置におけるThrのTyrへの置換;
配列番号1の820位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の821位に相当する位置におけるValのLys、Phe、Trp又はTyrへの置換;
配列番号1の823位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の824位に相当する位置におけるAlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
配列番号1の825位に相当する位置におけるGluのTyrへの置換;
配列番号1の826位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
配列番号1の827位に相当する位置におけるIleのPhe、Trp又はTyrへの置換;
配列番号1の830位に相当する位置におけるIleのPhe、Trp又はTyrへの置換;及び、
配列番号1の831位に相当する位置におけるLeuのPhe、Trp又はTyrへの置換、
からなる群より選択される少なくとも1つである、
〔2〕~〔4〕のいずれか1項記載の方法。
〔6〕前記少なくとも1つのアミノ酸残基の置換が、
好ましくは、以下:
配列番号1の817位に相当する位置におけるThrのTyrへの置換;
配列番号1の821位に相当する位置におけるValのLys、Phe、Trp又はTyrへの置換;
配列番号1の824位に相当する位置におけるAlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
配列番号1の825位に相当する位置におけるGluのTyrへの置換;及び、
配列番号1の826位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換、
からなる群より選択される少なくとも1つである、
〔5〕記載の方法。
〔7〕配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列が、
好ましくは、配列番号3の725~728位に相当する領域のアミノ酸残基を全て保持しており、より好ましくは、配列番号3の718~728位に相当する領域のアミノ酸残基を全て保持しており、
あるいは、
好ましくは、配列番号3の724~734位に相当する領域を保持しており、ただし該領域における一部のアミノ酸残基は変異していてもよい、
〔1〕~〔6〕のいずれか1項記載の方法。
〔8〕好ましくは、前記ポリペプチドの発現強化が、該ポリペプチドをコードする遺伝子の転写量を向上させることにより行われる、〔1〕~〔7〕のいずれか1項記載の方法。
〔9〕好ましくは、前記ポリペプチドをコードする遺伝子の転写量の向上が、制御領域と作動可能に連結された該ポリペプチドをコードする遺伝子を、親糸状菌に導入することにより行われる、〔8〕記載の方法。
〔10〕前記XYR1がXP_006966092.1として登録されている配列番号51のアミノ酸配列からなるポリペプチドであるか、又は配列番号51のアミノ酸配列と少なくとも90%配列同一なアミノ酸配列からなりかつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである場合、
前記少なくとも1つのアミノ酸残基の置換は、好ましくは、以下:
配列番号51の797位に相当する位置におけるThrのTyrへの置換;
配列番号51の801位に相当する位置におけるValのLys、Phe、Trp又はTyrへの置換;
配列番号51の804位に相当する位置におけるAlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
配列番号51の805位に相当する位置におけるGluのTyrへの置換;及び、
配列番号51の806位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換、
からなる群より選択される少なくとも1つである、
〔1〕~〔9〕のいずれか1項記載の方法。
〔11〕前記変異糸状菌が、
好ましくは、親糸状菌と比べてカタボライト抑制が緩和されており、
より好ましくは、セルラーゼ誘導性物質の非存在下でセルラーゼを発現する、
〔1〕~〔10〕のいずれか1項記載の方法。
〔12〕好ましくは、前記糸状菌がトリコデルマ属菌である、〔1〕~〔11〕のいずれか1項記載の方法。
〔13〕好ましくは、前記トリコデルマ属菌がトリコデルマ・リーセイ又はその変異株である、〔12〕記載の方法。
〔15〕好ましくは、前記タンパク質がセルラーゼ及び/又はヘミセルラーゼである、〔14〕記載の方法。
〔16〕好ましくは、前記培養がグルコース存在下で行われる、〔14〕又は〔15〕記載の方法。
該改変XYR1は、配列番号1又はこれと少なくとも90%配列同一なアミノ酸配列に対して、配列番号1の810~833位に相当する領域における少なくとも1つのアミノ酸残基が置換、欠失、挿入又は付加されたアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドであり、
該ACE3の部分ポリペプチドが、配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである、
変異糸状菌。
〔18〕好ましくは、配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列が、
好ましくは、配列番号3の725~728位に相当する領域のアミノ酸残基を全て保持しており、より好ましくは、配列番号3の718~728位に相当する領域のアミノ酸残基を全て保持しており、
あるいは、
好ましくは、配列番号3の724~734位に相当する領域を保持しており、ただし該領域における一部のアミノ酸残基は変異していてもよい、〔17〕記載の変異糸状菌。
〔19〕好ましくは、該改変XYR1が、配列番号1又はこれと少なくとも90%配列同一なアミノ酸配列に対して、配列番号1の810~833位に相当する領域における、以下からなる群より選択される少なくとも1つのアミノ酸残基の置換:
ValのLys、Phe、Trp又はTyrへの置換;
IleのPhe、Trp又はTyrへの置換;
LeuのPhe、Trp又はTyrへの置換;
AlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;及び、
GlyのVal、Ile、Leu、Phe、Trp又はTyrへの置換;
ThrのTyrへの置換;及び
GluのTyrへの置換、
がなされたアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである、
〔17〕又は〔18〕記載の変異糸状菌。
〔20〕好ましくは、該改変XYR1が、配列番号1と少なくとも90%配列同一であって、かつ以下の(a)~(m):
(a)配列番号1の812位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(b)配列番号1の814位に相当する位置におけるPhe、Trp又はTyr;
(c)配列番号1の816位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(d)配列番号1の817位に相当する位置におけるTyr;
(e)配列番号1の820位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(f)配列番号1の821位に相当する位置におけるLys、Phe、Trp又はTyr;
(g)配列番号1の823位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(h)配列番号1の824位に相当する位置におけるVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyr;
(i)配列番号1の825位に相当する位置におけるGluのTyrへの置換;
(j)配列番号1の826位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr;
(k)配列番号1の827位に相当する位置におけるPhe、Trp又はTyr;
(l)配列番号1の830位に相当する位置におけるPhe、Trp又はTyr;及び、
(m)配列番号1の831位に相当する位置におけるPhe、Trp又はTyr、
からなる群より選択される少なくとも1つのアミノ酸残基を有するアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである、
〔19〕記載の変異糸状菌。
〔21〕好ましくは、該改変XYR1が、配列番号1と少なくとも90%配列同一であって、かつ以下:
配列番号1の821位に相当する位置におけるLys、Phe、Trp又はTyr、好ましくはPhe、より好ましくはLys又はTyr;及び、
配列番号1の824位に相当する位置におけるVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyr、好ましくはVal、より好ましくはGlu、Ile、Leu、Lys、Phe、Thr、Trp又はTyr、
からなる群より選択される少なくとも1つのアミノ酸残基を有するアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである、
〔20〕記載の変異糸状菌。
〔22〕好ましくは、該改変XYR1が、配列番号1と少なくとも90%配列同一であって、かつ以下:
配列番号1の817位に相当する位置におけるTyr;
配列番号1の825位に相当する位置におけるTyr;及び、
配列番号1の826位に相当する位置におけるVal、Ile、Leu、Phe、Trp又はTyr、好ましくはVal又はTrp、
からなる群より選択される少なくとも1つのアミノ酸残基を有するアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドである、
〔20〕又は〔21〕記載の変異糸状菌。
トリコデルマ・リーセイのゲノムDNAを鋳型としたPCRにて、以下のDNA断片1~5を調製した。断片1:act1遺伝子(TRIREDRAFT_44504)の上流約1.5kbpのプロモーター領域、断片2:xyr1遺伝子(配列番号2、約3.0kbp)、断片3:ACE3の部分ポリペプチド(配列番号3の107~734位)をコードするポリヌクレオチド(配列番号4の881~2918番ヌクレオチド領域、約2.0kbp)、断片4:cbh1遺伝子(TRIREDRAFT_44504)の下流約0.6kbpのターミネーター領域、断片5:pyr4遺伝子(TRIREDRAFT_74020)の約2.7kbp領域。
断片1と2を結合してカセット1:Pact1-XYR1を構築した。断片1と3を結合してカセット2:Pact1-ACE3を構築した。断片5の上流及び下流に、それぞれ約0.5kbpの断片6と、約1.0kbpの断片7をポップアウト用の相同配列として配置した形質転換マーカー断片を調製した。断片4と該形質転換マーカー断片とを結合して、カセット3:Tcbh1-pyr4を構築した。DNA断片の結合はIn-Fusion HD Cloning Kit(タカラバイオ)のプロトコルに従って実施した。構築したカセット及びそれに含まれるDNA断片、ならびにカセットの構築に用いたプライマーを表1に示す。
カセット1と3を結合し、pUC118(タカラバイオ)のHincII制限酵素切断点に挿入して、xyr1恒常発現プラスミドpUC-Pact1-XYR1を構築した。またカセット2と3を結合、pUC118(タカラバイオ)のHincII制限酵素切断点に挿入して、ace3恒常発現プラスミドpUC-Pact1-ACE3を構築した。
トリコデルマ・リーセイJN13Δpyr4株は実施例1で構築したプラスミドを導入して形質転換した。プラスミド導入はプロトプラストPEG法(Biotechnol Bioeng,2012,109(1):92-99)により行った。形質転換体は、pyr4遺伝子をマーカーとして、選択培地(2%グルコース、1.1Mソルビトール、2%アガー、0.2% KH2PO4(pH5.5)、0.06% CaCl2・2H2O、0.06% CsCl2、0.06% MgSO4・7H2O、0.5% (NH4)2SO4、0.1% Trace element1;%はいずれもw/v%)にて選抜した。Trace element1の組成は以下のとおりである:0.5g FeSO4・7H2O、0.2g CoCl2、0.16g MnSO4・H2O、0.14g ZnSO4・7H2Oを蒸留水にて100mLにメスアップ。得られた形質転換体の中から、目的の遺伝子断片が挿入されていることをPCRにより確認し、pUC-Pact1-ACE3が導入されたJN13_ACE3株、及びpUC-Pact1-XYR1(V821F)が導入されたJN13_XYR1(V821F)株を得た。JN13_ACE3株は、ace3恒常発現プラスミドpUC-Pact1-ACE3によりACE3を高発現する。JN13_XYR1(V821F)株は、変異XYR1(V821F)を発現する。
実施例2で得た糸状菌株を培養してタンパク質を生産させた。前培養では、500mLのフラスコに培地を50mL仕込み、実施例2で作製した株の胞子を1×105個/mLとなるよう植菌し、28℃、220rpmにて振とう培養した(プリス社製PRXYg-98R)。培地組成は以下の通りである。1%グルコース、0.14% (NH4)2SO4、0.2% KH2PO4、0.03% CaCl2・2H2O、0.03% MgSO4・7H2O、0.1%ハイポリペプトンN、0.05% Bacto Yeast extract、0.1% Tween 80、0.1% Trace element2、50mM酒石酸バッファー(pH4.0)(%はいずれもw/v%)。Trace element2の組成は以下の通りである。6mg H3BO3、26mg (NH4)6Mo7O24・4H2O、100mg FeCl3・6H2O、40mg CuSO4・5H2O、8mg MnCl2・4H2O、200mg ZnCl2を蒸留水にて100mLにメスアップ。
実施例3の培養物のタンパク質濃度をbradford法にて測定した。bradford法では、Quick Startプロテインアッセイ(BioRad)を使用し、ウシγグロブリンを標準タンパク質として作成した検量線をもとにタンパク質量を計算した。グルコースのみを炭素源に用いた培養(グルコース培養)でのJN13株(親株)のタンパク質生産性を1としたときの、各株の相対タンパク質生産性を図1に示す。セルロース存在下での培養と比べて、グルコース培養での親株JN13のタンパク質生産性は大幅に低下した。これはグルコースのみを炭素源に用いた場合には誘導物質が存在せず、セルラーゼ群及びキシラナーゼ群の発現が転写活性化誘導されないためと推定される。XYR1とACE3の両方を改変したXYR1(V821F)+ACE3株及びXYR1(A824V)+ACE3株では、親株と比べて、さらにはXYR1とACE3の一方のみを改変したXYR1(V821F)株及びACE3株と比べても、グルコース培養でのタンパク質生産性が顕著に向上した。
実施例3の培養物のタンパク質組成を分析した。分析には、Mini PROTEAN TGX Stain-Free Gels(Any KD,15well,BIORAD)を用いた。スタンダードとして、Precision Plus Protein Unstained standarsを用いた。適宜希釈した実施例3の培養物とBufferを混合して99℃で5分間処理したものをゲルにアプライし、200V、35分間電気泳動した。得られた画像ファイル(図2)から、解析ソフト(Image Lab)を用いてバンド強度比率を計算し、生産されたタンパク質の組成比を計算した。該組成比と実施例4で求めたタンパク質濃度から各タンパク質の生産量を求めた。次いで、XYR1変異のみ(XYR1(V821F)株)でのタンパク質生産性を1として、各株での各タンパク質の相対生産性を算出した。
実施例1と同様の手順で、pUC-Pact1-XYR1を鋳型とする表4に示す配列番号23及び24のプライマーを用いたPCRにより、T817Yのアミノ酸置換がなされた変異XYR1を発現するプラスミドpUC-Pact1-XYR1(T817Y)を構築した。同様の手順で、表4に示すプライマーを用いてV821Y、V821K、A824I、A824L、A824F、A824W、A824Y、A824T、A824K、A824E、E825Y、A826V、及びA826Wのアミノ酸置換がなされた変異XYR1を発現するプラスミドをそれぞれ構築した。構築したプラスミドを、実施例2と同様の手法でJN13_ACE3Δpyr4株に対し形質転換することで、ACE3及び上記変異XYR1が導入された糸状菌変異株を得た。
Claims (13)
- 変異糸状菌の製造方法であって、
親糸状菌におけるXYR1及びACE3発現を改変することを含み、
該XYR1の改変が、配列番号1又はこれと少なくとも90%配列同一なアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドに対する、配列番号1の810~833位に相当する領域における少なくとも1つのアミノ酸残基の置換、欠失、挿入又は付加であり、
該ACE3発現の改変が、配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列からなるポリペプチドの発現強化である、
方法。 - 前記少なくとも1つのアミノ酸残基がVal、Ala、Thr及びGluからなる群より選択される少なくとも1つであり、かつ、該少なくとも1つのアミノ酸残基は置換される、請求項1記載の方法。
- 前記少なくとも1つのアミノ酸残基が、配列番号1の817位、821位、824位、825位及び826位に相当する位置におけるアミノ酸残基からなる群より選択される少なくとも1つである、請求項2記載の方法。
- 前記少なくとも1つのアミノ酸残基がそれぞれ、Val、Glu、Ile、Leu、Lys、Phe、Thr、Trp、又はTyrに置換される、請求項2又は3記載の方法。
- 前記少なくとも1つのアミノ酸の置換が、以下:
配列番号1の817位に相当する位置におけるThrのTyrへの置換;
配列番号1の821位に相当する位置のValのLys、Phe、Trp又はTyrへの置換;
配列番号1の824位に相当する位置のAlaのVal、Glu、Ile、Leu、Lys、Phe、Thr、Trp又はTyrへの置換;
配列番号1の825位に相当する位置におけるGluのTyrへの置換;及び、
配列番号1の826位に相当する位置におけるAlaのVal、Ile、Leu、Phe、Trp又はTyrへの置換、
からなる群より選択される、請求項2~4のいずれか1項記載の方法。 - 前記ポリペプチドの発現強化が、該ポリペプチドをコードする遺伝子の転写量を向上させることにより行われる、請求項1~5のいずれか1項記載の方法。
- 前記変異糸状菌がセルラーゼ誘導性物質の非存在下でセルラーゼを発現する、請求項1~6のいずれか1項記載の方法。
- 前記糸状菌がトリコデルマ属菌である、請求項1~7のいずれか1項記載の方法。
- 前記トリコデルマ属菌がトリコデルマ・リーセイである、請求項8記載の方法。
- 請求項1~9のいずれか1項記載の方法で製造された変異糸状菌を培養することを含む、タンパク質の製造方法。
- 前記タンパク質がセルラーゼ及び/又はヘミセルラーゼである、請求項10記載の方法。
- 前記培養がグルコース存在下で行われる、請求項8又は9記載の方法。
- 変異糸状菌であって、改変XYR1を含み、かつ親糸状菌と比べてACE3の部分ポリペプチドの発現が強化されており、
該改変XYR1は、配列番号1又はこれと少なくとも90%配列同一なアミノ酸配列に対して、配列番号1の810~833位に相当する領域における少なくとも1つのアミノ酸残基が置換、欠失、挿入又は付加されたアミノ酸配列からなり、かつセルラーゼ及びヘミセルラーゼの転写活性化因子として機能するポリペプチドであり、
該ACE3の部分ポリペプチドが、配列番号3の107~734位のアミノ酸配列又はこれと少なくとも90%配列同一なアミノ酸配列からなるポリペプチドである、
変異糸状菌。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/777,658 US20230042173A1 (en) | 2019-11-18 | 2020-11-13 | Mutant Filamentous Fungus, and Method for Producing Protein Using Same |
EP20890164.5A EP4063511A4 (en) | 2019-11-18 | 2020-11-13 | MUTANT FILAMENTOUS FUNGUS AND METHOD FOR PRODUCING PROTEIN USING SAME |
BR112022009620A BR112022009620A2 (pt) | 2019-11-18 | 2020-11-13 | Fungo filamentoso mutante e método para a produção de proteína usando o mesmo |
JP2021558354A JPWO2021100631A1 (ja) | 2019-11-18 | 2020-11-13 | |
CN202080080008.7A CN114729385A (zh) | 2019-11-18 | 2020-11-13 | 突变丝状菌和使用其的蛋白质的制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019208236 | 2019-11-18 | ||
JP2019-208236 | 2019-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021100631A1 true WO2021100631A1 (ja) | 2021-05-27 |
Family
ID=75981252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/042489 WO2021100631A1 (ja) | 2019-11-18 | 2020-11-13 | 変異糸状菌、及びそれを用いたタンパク質の製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230042173A1 (ja) |
EP (1) | EP4063511A4 (ja) |
JP (1) | JPWO2021100631A1 (ja) |
CN (1) | CN114729385A (ja) |
BR (1) | BR112022009620A2 (ja) |
WO (1) | WO2021100631A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113528492A (zh) * | 2021-09-07 | 2021-10-22 | 山东大学 | 一种将木质纤维素水解液回用于发酵生产纤维素酶液的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116064636A (zh) * | 2022-09-07 | 2023-05-05 | 山东大学 | 基于CRISPR/Cas9技术同步提升里氏木霉木聚糖酶活和纤维素酶活的方法及应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11512930A (ja) | 1995-09-01 | 1999-11-09 | ヴァルティオン・テクニッリネン・トゥトキムスケスクス | グルコース抑制の修飾法 |
JP5366286B2 (ja) | 2002-09-10 | 2013-12-11 | ジェネンコー・インターナショナル・インク | 高濃度糖類混合物を用いた遺伝子発現の誘発 |
JP2015039349A (ja) | 2013-08-22 | 2015-03-02 | 国立大学法人東北大学 | グルコース抑制遺伝子破壊株およびそれを利用した物質の生産方法 |
US9512415B2 (en) | 2010-06-04 | 2016-12-06 | Teknologian Tutkimuskeskus Vtt Oy | Method for protein production in filamentous fungi |
JP6169077B2 (ja) | 2011-08-19 | 2017-07-26 | イエフペ エネルジ ヌヴェルIfp Energies Nouvelles | 低い酸素移動容量係数KLaを有する、発酵槽に適した糸状菌を用いるセルラーゼの生産方法 |
WO2018067599A1 (en) | 2016-10-04 | 2018-04-12 | Danisco Us Inc. | Protein production in filamentous fungal cells in the absence of inducing substrates |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103436542B (zh) * | 2013-08-29 | 2014-09-17 | 山东大学 | 纤维素酶和半纤维素酶激活因子及其表达基因与应用 |
CN105802854B (zh) * | 2014-12-30 | 2020-10-16 | 中国科学院分子植物科学卓越创新中心 | 一种纤维素酶高产菌株及其应用 |
WO2017177289A1 (en) * | 2016-04-15 | 2017-10-19 | Vtt International Oy | Process for conversion of biomass into fermentable sugars with integrated enzyme |
CN106978360B (zh) * | 2017-04-24 | 2020-08-04 | 上海交通大学 | 一株高产纤维素酶里氏木霉重组菌株及其应用 |
CN108795988B (zh) * | 2017-05-04 | 2022-07-29 | 中国科学院分子植物科学卓越创新中心 | 木聚糖酶专性转录抑制因子及其在里氏木霉改造中的应用 |
-
2020
- 2020-11-13 JP JP2021558354A patent/JPWO2021100631A1/ja active Pending
- 2020-11-13 EP EP20890164.5A patent/EP4063511A4/en active Pending
- 2020-11-13 CN CN202080080008.7A patent/CN114729385A/zh active Pending
- 2020-11-13 US US17/777,658 patent/US20230042173A1/en active Pending
- 2020-11-13 BR BR112022009620A patent/BR112022009620A2/pt unknown
- 2020-11-13 WO PCT/JP2020/042489 patent/WO2021100631A1/ja unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11512930A (ja) | 1995-09-01 | 1999-11-09 | ヴァルティオン・テクニッリネン・トゥトキムスケスクス | グルコース抑制の修飾法 |
JP5366286B2 (ja) | 2002-09-10 | 2013-12-11 | ジェネンコー・インターナショナル・インク | 高濃度糖類混合物を用いた遺伝子発現の誘発 |
US9512415B2 (en) | 2010-06-04 | 2016-12-06 | Teknologian Tutkimuskeskus Vtt Oy | Method for protein production in filamentous fungi |
JP6169077B2 (ja) | 2011-08-19 | 2017-07-26 | イエフペ エネルジ ヌヴェルIfp Energies Nouvelles | 低い酸素移動容量係数KLaを有する、発酵槽に適した糸状菌を用いるセルラーゼの生産方法 |
JP2015039349A (ja) | 2013-08-22 | 2015-03-02 | 国立大学法人東北大学 | グルコース抑制遺伝子破壊株およびそれを利用した物質の生産方法 |
WO2018067599A1 (en) | 2016-10-04 | 2018-04-12 | Danisco Us Inc. | Protein production in filamentous fungal cells in the absence of inducing substrates |
JP2019528797A (ja) * | 2016-10-04 | 2019-10-17 | ダニスコ・ユーエス・インク | 誘導基質の非存在下における糸状菌細胞内でのタンパク質の産生 |
Non-Patent Citations (18)
Title |
---|
APPL. ENVIRON. MICROBIOL., vol. 63, 1997, pages 1298 - 1306 |
BIOTECH. BIOFUELS, vol. 10, 2017, pages 30 |
BIOTECH. BIOFUELS, vol. 13, 2020, pages 137 |
BIOTECH. BIOFUELS, vol. 6, 2013, pages 62 |
BIOTECHNOL. BIOENG., vol. 109, no. 1, 2012, pages 92 - 99 |
BMC GENOMICS, vol. 16, 2015, pages 326 |
CURR. GENOMICS, vol. 14, 2013, pages 230 - 249 |
DERTL, C. ET AL.: "Mutation of the Xylanase regulator 1 causes a glucose blind hydrolase expressing phenotype in industrially used Trichoderma strains", BIOTECHNOLOGY FOR BIOFUELS, vol. 6, no. 62, 2 May 2013 (2013-05-02), pages 1 - 11, XP021151509 * |
GENE, vol. 77, no. 1, 1989, pages 61 - 68 |
J. BIOL. CHEM., 2019 |
LICHIUS, A. ET AL.: "Erratum to: Genome sequencing of the Trichoderma reesei QM9136 mutant identifies a truncation of the transcriptional regulator XYR1 as the cause for its cellulase-negative phenotype", BMC GENOMICS, vol. 16, no. 725, 22 September 2015 (2015-09-22), pages 1, XP021216842 * |
LICHIUS, A. ET AL.: "Genome sequencing of the Trichoderma reesei QM9136 mutant identifies a truncation of the transcriptional regulator XYR1 as the cause for its cellulase-negative phenotype", BMC GENOMICS, vol. 16, no. 1, 20 April 2015 (2015-04-20), pages 1 - 20, XP021216842 * |
LUO, Y. ET AL.: "Modification of transcriptional factor ACE3 enhances protein production in Trichoderma reesei in the absence of cellulase gene inducer", BIOTECHNOLOGY FOR BIOFUELS, vol. 13, no. 1, 137, 6 August 2020 (2020-08-06), pages 1 - 16, XP055825631 * |
NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 7059 - 7071 |
SCIENCE, vol. 227, 1985, pages 1435 - 1441 |
See also references of EP4063511A4 |
THOMPSON, J. D. ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 4673 - 4680 |
ZHANG, J. ET AL.: "The transcription factor ACE3 controls cellulase activities and lactose metabolism via two additional regulators in the fungus Trichoderma reesei", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 294, no. 48, 29 November 2019 (2019-11-29), pages 18435 - 18450, XP055825541 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113528492A (zh) * | 2021-09-07 | 2021-10-22 | 山东大学 | 一种将木质纤维素水解液回用于发酵生产纤维素酶液的方法 |
Also Published As
Publication number | Publication date |
---|---|
BR112022009620A2 (pt) | 2022-08-02 |
CN114729385A (zh) | 2022-07-08 |
US20230042173A1 (en) | 2023-02-09 |
EP4063511A4 (en) | 2024-03-27 |
JPWO2021100631A1 (ja) | 2021-05-27 |
EP4063511A1 (en) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105189730B (zh) | 淀粉酶缺陷菌株 | |
JP7285780B2 (ja) | 誘導基質の非存在下における糸状菌細胞内でのタンパク質の産生 | |
CA2803222A1 (en) | A method for the production of a compound of interest | |
WO2021100631A1 (ja) | 変異糸状菌、及びそれを用いたタンパク質の製造方法 | |
DK3036324T3 (en) | Regulated PepC expression | |
EP1799821A2 (en) | Homologous amds genes as selectable marker | |
US10844100B2 (en) | Mutant strain of filamentous fungus and use therefor | |
CN104619853B (zh) | 多肽表达方法 | |
EP2062967A1 (en) | Genetically engineered aspergillus | |
WO2022215618A1 (ja) | 改変糸状菌、及びそれを用いたタンパク質の製造方法 | |
JP5148879B2 (ja) | 難発現性タンパク質の分泌のためのタンパク質融合因子(tfp)を明らかにする方法、タンパク質融合因子(tfp)ライブラリーを製造する方法、及び難発現性タンパク質の組み換え的生産方法 | |
WO2024004983A1 (ja) | エリスリトール資化能欠損変異トリコデルマ属菌、及びこれを用いた目的物質の製造方法 | |
KR20210038591A (ko) | 향상된 단백질 생산성 표현형을 포함하는 돌연변이체 및 유전자 변형된 사상성 진균 균주 및 이의 방법 | |
JP7398371B2 (ja) | タンパク質の製造方法 | |
WO2023074901A1 (ja) | エリスリトール誘導性プロモーター、及びこれを用いた目的物質の製造方法 | |
CN112105740A (zh) | 真菌宿主中的长链非编码rna表达 | |
JP6085190B2 (ja) | 変異微生物及びそれを用いた有用物質の生産方法 | |
JP5732209B2 (ja) | 遺伝子発現方法 | |
JP2004129576A (ja) | 超耐熱性エンドグルカナーゼの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20890164 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021558354 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022009620 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020890164 Country of ref document: EP Effective date: 20220620 |
|
ENP | Entry into the national phase |
Ref document number: 112022009620 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220517 |